Trading Halt
Open PDF
| Stock | Syntara Ltd (SNT.ASX) |
|---|---|
| Release Time | 27 Apr 2026, 9:22 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Syntara Ltd Requests Trading Halt
Key Points
- Trading halt requested pending announcement on FDA correspondence
- Halt to remain until earlier of market open on April 29 or announcement release
- Company not aware of any other information to disclose regarding the trading halt
Full Summary
Syntara Ltd has requested an immediate trading halt in its shares (ASX: SNT) pending an announcement regarding correspondence from the U.S. Food and Drug Administration (FDA) following their review of a proposed clinical development pathway, and specifically a Phase 2b trial protocol, for the company's lead asset Amsulostat. The trading halt will remain in place until the earlier of the commencement of trading on Wednesday, 29 April 2026 and the time at which the company makes an announcement to the market in relation to the FDA correspondence. The company confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In